Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, Cohen BM, Pope HG Jr, Renshaw PF, Ong├╝r D.

Neuropsychopharmacology. 2010 Feb;35(3):834-46. doi: 10.1038/npp.2009.191. Epub 2009 Dec 2.

2.

Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys.

Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, Borges G, Bromet E, Bruffaerts R, de Girolamo G, de Graaf R, Florescu S, Gureje O, Haro JM, Hu C, Huang Y, Karam EG, Kawakami N, Kovess V, Levinson D, Posada-Villa J, Sagar R, Tomov T, Viana MC, Williams DR.

PLoS Med. 2009 Aug;6(8):e1000123. doi: 10.1371/journal.pmed.1000123. Epub 2009 Aug 11.

3.

Bipolar disorder: from genes to behavior pathways.

Martinowich K, Schloesser RJ, Manji HK.

J Clin Invest. 2009 Apr;119(4):726-36. doi: 10.1172/JCI37703. Review.

4.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
5.

Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study.

Altamura AC, Dell'Osso B, Buoli M, Zanoni S, Mundo E.

J Clin Psychopharmacol. 2008 Aug;28(4):406-10. doi: 10.1097/JCP.0b013e31817d5931.

PMID:
18626267
6.
7.

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr.

J Clin Psychiatry. 2008 Jun;69(6):946-58. Review.

8.

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Sanacora G, Zarate CA, Krystal JH, Manji HK.

Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462. Review.

9.

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.

Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA.

Bipolar Disord. 2008 Mar;10(2):323-33. doi: 10.1111/j.1399-5618.2007.00500.x.

PMID:
18271912
10.

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK.

Biol Psychiatry. 2008 Feb 15;63(4):349-52. Epub 2007 Jul 23.

PMID:
17643398
11.

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.

Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

Arch Gen Psychiatry. 2007 May;64(5):543-52. Erratum in: Arch Gen Psychiatry. 2007 Sep;64(9):1039.

12.

Effectiveness of adjunctive antidepressant treatment for bipolar depression.

Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME.

N Engl J Med. 2007 Apr 26;356(17):1711-22. Epub 2007 Mar 28.

13.

Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH.

Brain Res. 2007 Jan 5;1127(1):108-18. Epub 2006 Nov 17.

14.

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group.

J Clin Psychopharmacol. 2006 Dec;26(6):600-9. Erratum in: J Clin Psychopharmacol. 2007 Feb;27(1):51.

PMID:
17110817
15.
16.

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.

Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate CA Jr, Manji HK.

Neuropsychopharmacology. 2007 Apr;32(4):793-802. Epub 2006 Aug 16.

17.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK.

Arch Gen Psychiatry. 2006 Aug;63(8):856-64.

PMID:
16894061
18.

N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels.

Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N, Kennedy JL.

Schizophr Res. 2006 Jun;84(2-3):214-21. Epub 2006 Mar 20.

PMID:
16549338
19.

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.

Zarate CA Jr, Singh J, Manji HK.

Biol Psychiatry. 2006 Jun 1;59(11):1006-20. Epub 2006 Feb 17. Review.

PMID:
16487491
20.

Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.

Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS.

Am J Psychiatry. 2006 Feb;163(2):210-6.

PMID:
16449473
Items per page

Supplemental Content

Write to the Help Desk